Information Provided By: 
Fly News Breaks for March 2, 2017
JUNO
Mar 2, 2017 | 08:27 EDT
Maxim analyst Jason McCarthy noted the "disappointment" of Juno Therapeutics opting to discontinue development of JCAR015 in Acute Lymphoblastic Leukemia, or ALL, but also said the company has a number of CARs in development that have demonstrated positive data, with more data on the way this year. With the focus now on JCAR017 in nonHodgkin lymphoma, or NHL, and the company expecting to have more than 20 trials enrolling in 2017, McCarthy keeps a Buy rating and $34 price target on Juno shares, which are down 7% to $23.50 in pre-market trading.
News For JUNO From the Last 2 Days
There are no results for your query JUNO
